ClinicalTrials.gg
RecruitingNCT06623981Updated Nov 17, 2026

The Exhale Study: Treating Maternal Depression in an Urban Pediatric Asthma Clinic

An interventional study of Enhanced Brief Interpersonal Psychotherapy and Supplemented Usual Care in Asthma in Children and Depression, sponsored by Children's National Research Institute. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Children's National Research Institute · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.
Updated Nov 17, 2026Study completion movedStudy contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,715 studies in Depression with a site in United States — 579 open to participants now, 716 under way, 29 of them phase 3. Depression · United States.

Planned enrollment
1,787th of 3,322
60 · median 72
Started
2024
with 212 others
No phase
2,221 of 3,715
386 open now
Primary completion
2026-12
later than 157 of 714 live
Registered
3,308th of 3,715
by date

Among the 3,715 studies in Depression with a site in United States, this one is the 1,787th largest by planned enrollment of the 3,322 interventional ones that give a count, is one of 213 that started in 2024, is one of 2,221 with no phase, reaches primary completion later than 157 of the 714 other live ones, and was the 3,308th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

579 of the 3,715 studies in Depression with a site in United States are open now. Recruiting first, the newest first:

574 more — sign in →

All 579 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,715 studies in Depression with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test the effectiveness and implementation of delivering Enhanced Brief Interpersonal Psychotherapy (IPT-B), an evidence-based maternal depression treatment, to mothers of children under the age of 18 in an urban pediatric asthma clinic. Researchers will compare Enhanced IPT-B and supplemented usual care (brief care coordination). The main questions the trial aims to answer are:

  1. Does Enhanced IPT-B decrease maternal depressive symptoms?
  2. Does Enhanced IPT-B improve child asthma management and health outcomes (exacerbations, symptoms, control)?
  3. What are the preliminary implementation outcomes of delivering Enhanced IPT-B in an urban pediatric asthma clinic?
Read the detailed description

The purpose of the study is to determine the effectiveness and implementation of Brief Enhanced Interpersonal Psychotherapy (IPT-B), an evidence-based treatment for maternal depression, delivered in an urban pediatric asthma clinic. This study is a pilot Hybrid Type 1 Effectiveness-Implementation, single-blinded, prospective randomized controlled trial. A parallel two-group design will be used to evaluate the impact of the intervention (Enhanced IPT-B) among a sample of 48 Black mothers of children under the age of 18 with asthma. Mothers with PHQ-9 ≥ 8 will be identified in the asthma clinic through routine depression screening during the child's visit and recruited to participate in the study if they meet eligibility criteria. Following the informed consent process, mothers randomized to the intervention group will receive Enhanced IPT-B. Enhanced IPT-B consists of a single, 45-60-minute pre-treatment engagement session followed by eight weekly, 45-minute individual psychotherapy sessions carried out by a licensed mental health clinician within an 8-12-week timeframe. Mothers randomized to the comparison group will receive Supplemented Usual Care which involves short-term care coordination to access community mental health resources. Data on maternal mental health, child asthma management and outcomes, and child mental health will be collected from mothers and children at baseline, 3 months post-baseline, and 6 months post-baseline. Data on implementation outcomes will be collected from mothers and asthma clinic leadership and staff. Quantitative and qualitative data analysis strategies will be utilized to answer the research questions.

03

Conditions studied

  • Asthma in Children
  • Depression

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Maternal:

  • Primary caregiver of the child with asthma seen at the community-based asthma clinic
  • Female (self-identified)
  • Black (self-identified)
  • ≥ 18 years of age
  • English-speaking
  • PHQ-9 ≥ 8 during standardized screening at the child with asthma's clinic visit

Child:

  • \<18 years old for the duration of the 6-month study period
  • Publicly insured
  • Physician-diagnosed persistent asthma

Exclusion criteria

Exclusion Criteria:

Maternal:

  • Acutely suicidal (high risk on the C-SSRS at child's asthma clinic visit)
  • Bipolar disorder or mania
  • Schizophrenia
  • Current substance abuse/dependence
  • Current serious physical intimate partner violence (IPV)
  • Lack of capacity to meaningfully participate in study procedures, as assessed by study staff during screening

Child:

  • Significant medical co-morbidity (e.g., disorders of the cardiorespiratory system, significant developmental delay, diabetes, seizure disorder, and sickle cell disease)
  • Enrolled in another intervention with a behavioral component and/or novel asthma therapeutics
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Enhanced IPT-B

    Enhanced Brief Interpersonal Psychotherapy

    Behavioral: Enhanced Brief Interpersonal Psychotherapy

  • Active comparator
    Supplemented Usual Care

    Short-term care coordination

    Behavioral: Supplemented Usual Care

Interventions

  • BehavioralEnhanced Brief Interpersonal Psychotherapy

    Enhanced IPT-B consists of a single, 45-60-minute pre-treatment engagement session followed by eight weekly, 45-minute individual sessions carried out within an 8-12-week timeframe.

  • BehavioralSupplemented Usual Care

    Usual care for caregivers with depressive symptoms involves the asthma clinic physician discussing the PHQ-9 results with the caregiver, providing brief psychoeducation on depression and giving the caregiver a written list of mental health resources. Usual care will be supplemented by providing short-term care coordination. Care coordination will involve assisting the participant in calling a mental health clinic to make an appointment and one follow-up phone call within two weeks.

06

What researchers measure

Primary outcomes

  1. Maternal depressive symptoms

    ≥ 50% reduction in depressive symptoms on the 9-item Patient Health Questionnaire (PHQ-9) at T2. The PHQ-9 score ranges from 0-27, with higher scores indicating more depressive symptoms. This variable will be dichotomized into 50% or greater reduction in depressive symptoms vs. less than 50% reduction in depressive symptoms from T1 to T2.

    Time frame: T2 (3 months post-baseline)

Secondary outcomes

  1. Clinically significant maternal depressive symptoms

    9-item Patient Health Questionnaire (PHQ-9) score less than 10 (i.e., not clinically significant) at T2. The PHQ-9 score ranges from 0-27, with higher scores indicating more depressive symptoms. A score of 10 or more indicates clinically significant symptoms. This variable will be dichotomized into clinically significant and not clinically significant.

    Time frame: T2 (3 months post-baseline)

  2. Child asthma exacerbations

    Number of asthma exacerbations requiring steroids in the past 6 months

    Time frame: T3 (6 months post-baseline)

  3. Child asthma symptoms

    Mother-reported number of child asthma symptom-free days during the prior 14 days

    Time frame: T2 (3 months post-baseline), T3 (6 months post-baseline)

  4. Maintenance

    Percentage of enrolled mothers who remain in the study

    Time frame: T3 (6 months post-baseline)

  5. Acceptability

    Mean treatment satisfaction survey score on the Client Satisfaction Questionnaire

    Time frame: T2 (3 months post-baseline)

  6. Maternal anxiety symptoms

    Scores on the 7-item Generalized Anxiety Disorder sale (GAD-7). Scores range from 0-21, with higher scores indicating more anxiety.

    Time frame: T2 (3-months post-baseline) and T3 (6months post-baseline)

  7. Maternal PTSD symptoms

    Score on the PTSD Checklist for DSM-5 (PCL-5), a validated self-report measure of PTSD symptoms in adults. Scores on the PCL-5 range from 0-80, with higher scores indicating more PTSD symptoms.

    Time frame: T2 (3 months post-baseline) and T3 (6 months post-baseline)

  8. Child depressive symptoms

    Mother report of child depressive symptoms on the PROMIS Parent Proxy Depressive Symptoms v3.0- Short Form 6a. Raw scores on the measure range from 6-30, with higher scores indicating more depressive symptoms.

    Time frame: T2 (3 months post-baseline) and T3 (6 months post-baseline)

  9. Child anxiety symptoms

    Mother report of child anxiety symptoms on the PROMIS Parent Proxy Short Form GenPop v3.0 - Anxiety 8a. Raw scores on the measure range from 8-40, with higher scores indicating more anxiety symptoms.

    Time frame: T2 (3 months post-baseline) and T3 (6 months post-baseline)

  10. Child asthma control

    Dichotomized score on the Child Asthma Control Test where ACT ≥ 20 indicates controlled asthma and ACT less than 20 indicates uncontrolled asthma.

    Time frame: T2 (3 months post-baseline), T3 (6 months post-baseline)

  11. Asthma management

    Summary score on the Family Asthma Management System Scale (FAMSS), a clinical interview that assesses how well the family system manages the asthma of the child. The interview is recorded and rated on eight 9-point subscales that tap the various domains of asthma management, with higher scores indicating better management.

    Time frame: T2 (3 months post-baseline)

  12. Reach

    The number and proportion of eligible mothers recruited into the study

    Time frame: T1 (Baseline)

  13. Feasibility

    Percentage of mothers who complete at least 7 sessions of the intervention (Enhanced IPT-B)

    Time frame: T2 (3 months post-baseline)

  14. Satisfaction

    Semi-structured interviews will be conducted with study participants to assess satisfaction with the Exhale Study , and for those who received Enhanced IPT-B, satisfaction with the intervention .

    Time frame: T3 (6 months post-baseline)

  15. Staff-reported implementation outcomes (adoption, acceptability, maintenance)

    Semi-structured qualitative interviews with asthma clinic staff and leadership to assess adoption, acceptability, and maintenance of the intervention.

    Time frame: Following completion of final participant follow-up (approximately Month 36)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual and aggregate survey data (including raw and recoded data) will be shared. The data from intervention sessions with Enhanced IPT-B participants will not be shared. Summarized aggregated deidentified data from the implementation-focused process evaluation will be made available for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: The study data will be released and made available approximately 12 months following the conclusion of the award period. Datasets underlying publications will be shared at or prior to initial publication date. Data we do not publish on will be shared before the end of this award. Study data deposited in the DSDR repository will be available to the research community permanently.

Access criteria: All shared study materials, data, and metadata will be made publicly available to researchers external to the project free of charge through the Data Sharing for Demographic Research (DSDR) digital data repository hosted by the ICPSR. The data will be findable in the DSDR repository and identifiable using a study digital object identifier provided by ICPSR.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 26 months is above that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

Completion moved once since we started tracking on Sep 25, 2026: Mar 2027 → Jun 2027, on Nov 17, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2024
First posted
Oct 2, 2024
StartActual
Oct 15, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2027was Mar 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Mar 15, 2027→Jun 2027
Nov 17, 2026
Secondary outcomes
1 edited, 1 description edited
What changed in the outcomes
  • EditedStaff-reported implementation outcomes (adoption, acceptability, maintenance)Time frame: At the end of year 2 → Following completion of final participant follow-up (approximately Month 36)
  • DescriptionSatisfaction: how it is measured was reworded
Nov 17, 2026
Contact
Study contact changed: G•••@childrensnational.org · •••6956→C•••@childrensnational.org · •••4544. See the current contact
Nov 17, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Children's National Hospital · Washington D.C., United StatesContact G•••@childrensnational.org · •••6956→c•••@childrensnational.org · •••4544
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Study completion Mar 15, 2027→Jun 2027
    Secondary outcomes 1 edited, 1 description edited
    What changed in the outcomes
    • EditedStaff-reported implementation outcomes (adoption, acceptability, maintenance)Time frame: At the end of year 2 → Following completion of final participant follow-up (approximately Month 36)
    • DescriptionSatisfaction: how it is measured was reworded
    Contact Study contact changed: G•••@childrensnational.org · •••6956→C•••@childrensnational.org · •••4544. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Children's National Hospital · Washington D.C., United StatesContact G•••@childrensnational.org · •••6956→c•••@childrensnational.org · •••4544
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06623981
Responsible party
Sponsor
First posted
Oct 2, 2024
Start date
Oct 15, 2024
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Celeste Beauvilaire
Contact
CBEAUVILAI@childrensnational.org
(202) 476-4544
Rachel Margolis, PhD, MSW
principal investigator · Children's National Research Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion